776 related articles for article (PubMed ID: 11465522)
1. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.
Landén M; Björling G; Agren H; Fahlén T
J Clin Psychiatry; 1998 Dec; 59(12):664-8. PubMed ID: 9921700
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
Burke WJ; Gergel I; Bose A
J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
[TBL] [Abstract][Full Text] [Related]
4. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes.
Barbosa L; Berk M; Vorster M
J Clin Psychiatry; 2003 Apr; 64(4):403-7. PubMed ID: 12716240
[TBL] [Abstract][Full Text] [Related]
6. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.
Feighner JP; Overø K
J Clin Psychiatry; 1999 Dec; 60(12):824-30. PubMed ID: 10665628
[TBL] [Abstract][Full Text] [Related]
7. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
Bielski RJ; Ventura D; Chang CC
J Clin Psychiatry; 2004 Sep; 65(9):1190-6. PubMed ID: 15367045
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
Pérez V; Soler J; Puigdemont D; Alvarez E; Artigas F
Arch Gen Psychiatry; 1999 Apr; 56(4):375-9. PubMed ID: 10197835
[TBL] [Abstract][Full Text] [Related]
9. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
Mao PX; Tang YL; Jiang F; Shu L; Gu X; Li M; Qian M; Ma C; Mitchell PB; Cai ZJ
Depress Anxiety; 2008; 25(1):46-54. PubMed ID: 17149753
[TBL] [Abstract][Full Text] [Related]
10. Medication augmentation after the failure of SSRIs for depression.
Trivedi MH; Fava M; Wisniewski SR; Thase ME; Quitkin F; Warden D; Ritz L; Nierenberg AA; Lebowitz BD; Biggs MM; Luther JF; Shores-Wilson K; Rush AJ;
N Engl J Med; 2006 Mar; 354(12):1243-52. PubMed ID: 16554526
[TBL] [Abstract][Full Text] [Related]
11. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression.
Fischer P; Tauscher J; Küfferle B; Kasper S
Int Clin Psychopharmacol; 1998 Mar; 13(2):83-6. PubMed ID: 9669189
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
Costa e Silva J
J Clin Psychiatry; 1998 Jul; 59(7):352-7. PubMed ID: 9714263
[TBL] [Abstract][Full Text] [Related]
13. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.
Landén M; Högberg P; Thase ME
J Clin Psychiatry; 2005 Jan; 66(1):100-6. PubMed ID: 15669895
[TBL] [Abstract][Full Text] [Related]
14. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.
Joffe RT; Schuller DR
J Clin Psychiatry; 1993 Jul; 54(7):269-71. PubMed ID: 8335654
[TBL] [Abstract][Full Text] [Related]
15. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response.
Wade AG; Crawford GM; Nemeroff CB; Schatzberg AF; Schlaepfer T; McConnachie A; Haazen L; Buntinx E
Psychol Med; 2011 Oct; 41(10):2089-97. PubMed ID: 21349239
[TBL] [Abstract][Full Text] [Related]
16. Buspirone and imipramine for the treatment of major depression in the elderly.
Schweizer E; Rickels K; Hassman H; Garcia-España F
J Clin Psychiatry; 1998 Apr; 59(4):175-83. PubMed ID: 9590668
[TBL] [Abstract][Full Text] [Related]
17. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
Corya SA; Perlis RH; Keck PE; Lin DY; Case MG; Williamson DJ; Tohen MF
J Clin Psychiatry; 2006 May; 67(5):798-806. PubMed ID: 16841630
[TBL] [Abstract][Full Text] [Related]
18. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
Mallick R; Chen J; Entsuah AR; Schatzberg AF
J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
[TBL] [Abstract][Full Text] [Related]
19. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
[TBL] [Abstract][Full Text] [Related]
20. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction.
Spigset O; Adielsson G
Int Clin Psychopharmacol; 1997 Jan; 12(1):61-3. PubMed ID: 9179637
[No Abstract] [Full Text] [Related]
[Next] [New Search]
